This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer.
Ozempic MDL Expands to Include New Drugs, but Not New Injuries
"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...
Ozempic lures people to the doctor, Nestle's GLP-1 'shot,' an FDA Zepbound ruling: Pharma news roundup
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
FDA: Knockoff versions of Lilly obesity drug must come off the market
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes ...
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
NJBIZ2d
EU reportedly reviewing link between Ozempic, rare eye disease
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
FiercePharma2d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
FDA says Lilly weight loss drug shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies
Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...